Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit
/PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat...
United States Ignacio Guerrero Ros Davej Bearss Russo Partners Company Contact Halia Therapeutics Inc
Source: prnewswire.com